You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 12, December 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Alzheimer Disease
 •Cognitive Disorders
 •Prognosis/ Outcomes
 •Alert me on articles by topic

Disruptive Behavior as a Predictor in Alzheimer Disease

Nikolaos Scarmeas, MD, MS; Jason Brandt, PhD; Deborah Blacker, MD, ScD; Marilyn Albert, PhD; Georgios Hadjigeorgiou, MD; Bruno Dubois, MD; Davangere Devanand, MD; Lawrence Honig, MD, PhD; Yaakov Stern, PhD

Arch Neurol. 2007;64(12):1755-1761.

Background  Disruptive behavior is common in Alzheimer disease (AD). There are conflicting reports regarding its ability to predict cognitive decline, functional decline, institutionalization, and mortality.

Objective  To examine whether the presence of disruptive behavior has predictive value for important outcomes in AD.

Design  Using the Columbia University Scale for Psychopathology in Alzheimer Disease (administered every 6 months, for a total of 3438 visit-assessments and an average of 6.9 per patient), the presence of disruptive behavior (wandering, verbal outbursts, physical threats/violence, agitation/restlessness, and sundowning) was extracted and examined as a time-dependent predictor in Cox models. The models controlled for the recruitment cohort, recruitment center, informant status, sex, age, education, a comorbidity index, baseline cognitive and functional performance, and neuroleptic use.

Setting  Five university-based AD centers in the United States and Europe (Predictors Study).

Participants  Four hundred ninety-seven patients with early-stage AD (mean Folstein Mini-Mental State Examination score, 20 of 30 at entry) who were recruited and who underwent semiannual follow-up for as long as 14 (mean, 4.4) years.

Main Outcome Measures  Cognitive (Columbia Mini-Mental State Examination score, ≤ 20 of 57 [approximate Folstein Mini-Mental State Examination score, ≤ 10 of 30]) and functional (Blessed Dementia Rating Scale score, parts I and II, ≥ 10) ratings, institutionalization equivalent index, and death.

Results  At least 1 disruptive behavioral symptom was noted in 48% of patients at baseline and in 83% at any evaluation. Their presence was associated with increased risks of cognitive decline (hazard ratio 1.45 [95% confidence interval (CI), 1.03-2.03]), functional decline (1.66 [95% CI, 1.17-2.36]), and institutionalization (1.47 [95% CI, 1.10-1.97]). Sundowning was associated with faster cognitive decline, wandering with faster functional decline and institutionalization, and agitation/restlessness with faster cognitive and functional decline. There was no association between disruptive behavior and mortality (hazard ratio, 0.94 [95% CI, 0.71-1.25]).

Conclusion  Disruptive behavior is very common in AD and predicts cognitive decline, functional decline, and institutionalization but not mortality.


Author Affiliations: Cognitive Neuroscience Division, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, the Gertrude H. Sergievsky Center (Drs Scarmeas, Devanand, Honig, and Stern), and the Departments of Neurology (Drs Scarmeas, Honig, and Stern) and Psychiatry (Drs Devanand and Stern), Columbia University Medical Center, New York, New York; Departments of Psychiatry and Behavioral Sciences and Neurology, The Johns Hopkins University, Baltimore, Maryland (Drs Brandt and Albert); Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Blacker); and Departments of Neurology, University of Thessaly, Larissa, Greece (Dr Hadjigeorgiou), and Hospital de la Salpêtrière, Paris, France (Dr Dubois).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.